152 related articles for article (PubMed ID: 33494392)
1. A Regulatory Loop of FBXW7-MYC-PLK1 Controls Tumorigenesis of MYC-Driven Medulloblastoma.
Wang D; Pierce A; Veo B; Fosmire S; Danis E; Donson A; Venkataraman S; Vibhakar R
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33494392
[TBL] [Abstract][Full Text] [Related]
2. A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
Wang D; Veo B; Pierce A; Fosmire S; Madhavan K; Balakrishnan I; Donson A; Alimova I; Sullivan KD; Joshi M; Erlander M; Ridinger M; Foreman NK; Venkataraman S; Vibhakar R
Neuro Oncol; 2022 Mar; 24(3):414-426. PubMed ID: 34477871
[TBL] [Abstract][Full Text] [Related]
3. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
[TBL] [Abstract][Full Text] [Related]
4. Polo-Like Kinase 1 phosphorylates and stabilizes KLF4 to promote tumorigenesis in nasopharyngeal carcinoma.
Mai J; Zhong ZY; Guo GF; Chen XX; Xiang YQ; Li X; Zhang HL; Chen YH; Xu XL; Wu RY; Yu Y; Li ZL; Peng XD; Huang Y; Zhou LH; Feng GK; Guo X; Deng R; Zhu XF
Theranostics; 2019; 9(12):3541-3554. PubMed ID: 31281496
[No Abstract] [Full Text] [Related]
5. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG
Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075
[TBL] [Abstract][Full Text] [Related]
6. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
[TBL] [Abstract][Full Text] [Related]
7. Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells.
Valinciute G; Ecker J; Selt F; Hielscher T; Sigaud R; Ridinger J; Thatikonda V; Gatzweiler C; Robinson S; Talbot J; Bernardi F; Picard D; Blattner-Johnson M; Schmid S; Jones DT; van Tilburg CM; Capper D; Kool M; Remke M; Oehme I; Pfister SM; Roussel MF; Ayrault O; Witt O; Milde T
J Neurooncol; 2023 May; 163(1):143-158. PubMed ID: 37183219
[TBL] [Abstract][Full Text] [Related]
8. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.
Triscott J; Lee C; Foster C; Manoranjan B; Pambid MR; Berns R; Fotovati A; Venugopal C; O'Halloran K; Narendran A; Hawkins C; Ramaswamy V; Bouffet E; Taylor MD; Singhal A; Hukin J; Rassekh R; Yip S; Northcott P; Singh SK; Dunham C; Dunn SE
Cancer Res; 2013 Nov; 73(22):6734-44. PubMed ID: 24019381
[TBL] [Abstract][Full Text] [Related]
9. Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.
Alimova I; Pierce AM; Harris P; Donson A; Birks DK; Prince E; Balakrishnan I; Foreman NK; Kool M; Hoffman L; Venkataraman S; Vibhakar R
Oncotarget; 2017 Nov; 8(57):97290-97303. PubMed ID: 29228610
[TBL] [Abstract][Full Text] [Related]
10. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.
Wang J; Wang H; Peters M; Ding N; Ribback S; Utpatel K; Cigliano A; Dombrowski F; Xu M; Chen X; Song X; Che L; Evert M; Cossu A; Gordan J; Zeng Y; Chen X; Calvisi DF
J Hepatol; 2019 Oct; 71(4):742-752. PubMed ID: 31195063
[TBL] [Abstract][Full Text] [Related]
11. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
12. NSD3S stabilizes MYC through hindering its interaction with FBXW7.
Gonzalez-Pecchi V; Kwan AK; Doyle S; Ivanov AA; Du Y; Fu H
J Mol Cell Biol; 2020 Jul; 12(6):438-447. PubMed ID: 31638140
[TBL] [Abstract][Full Text] [Related]
13. Opposing functions of Fbxw7 in keratinocyte growth, differentiation and skin tumorigenesis mediated through negative regulation of c-Myc and Notch.
Ishikawa Y; Hosogane M; Okuyama R; Aoyama S; Onoyama I; Nakayama KI; Nakayama K
Oncogene; 2013 Apr; 32(15):1921-32. PubMed ID: 22665065
[TBL] [Abstract][Full Text] [Related]
14. Role of MYC-miR-29-B7-H3 in Medulloblastoma Growth and Angiogenesis.
Purvis IJ; Avilala J; Guda MR; Venkataraman S; Vibhakar R; Tsung AJ; Velpula KK; Asuthkar S
J Clin Med; 2019 Aug; 8(8):. PubMed ID: 31382461
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Fbxw7 expression and its correlation with the expression of c-Myc, cyclin E and p53 in human hepatocellular carcinoma.
Tu K; Zheng X; Zan X; Han S; Yao Y; Liu Q
Hepatol Res; 2012 Sep; 42(9):904-10. PubMed ID: 22548670
[TBL] [Abstract][Full Text] [Related]
16. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells.
von Bueren AO; Shalaby T; Rajtarova J; Stearns D; Eberhart CG; Helson L; Arcaro A; Grotzer MA
BMC Cancer; 2007 Jan; 7():19. PubMed ID: 17254356
[TBL] [Abstract][Full Text] [Related]
17. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
Bolin S; Borgenvik A; Persson CU; Sundström A; Qi J; Bradner JE; Weiss WA; Cho YJ; Weishaupt H; Swartling FJ
Oncogene; 2018 May; 37(21):2850-2862. PubMed ID: 29511348
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional Regulation of Protein Synthesis by Mediator Kinase in MYC-driven Medulloblastoma.
Wang D; Ritz C; Pierce A; Brunt B; Luo Y; Dahl N; Venkataraman S; Danis E; Kuś K; Mazan M; Rzymski T; Veo B; Vibhakar R
bioRxiv; 2024 Mar; ():. PubMed ID: 38559100
[TBL] [Abstract][Full Text] [Related]
19. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.
Ren Y; Bi C; Zhao X; Lwin T; Wang C; Yuan J; Silva AS; Shah BD; Fang B; Li T; Koomen JM; Jiang H; Chavez JC; Pham LV; Sudalagunta PR; Wan L; Wang X; Dalton WS; Moscinski LC; Shain KH; Vose J; Cleveland JL; Sotomayor EM; Fu K; Tao J
J Clin Invest; 2018 Dec; 128(12):5517-5530. PubMed ID: 30260324
[TBL] [Abstract][Full Text] [Related]
20. N6-Isopentenyladenosine Inhibits Colorectal Cancer and Improves Sensitivity to 5-Fluorouracil-Targeting FBXW7 Tumor Suppressor.
Fiore D; Piscopo C; Proto MC; Vasaturo M; Dal Piaz F; Fusco BM; Pagano C; Laezza C; Bifulco M; Gazzerro P
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
